BioSight
Companies
EXELIXIS, INC. logo

EXEL

NASDAQALAMEDA, CA
EXELIXIS, INC.

Exelixis is an oncology company with four marketed products including cabozantinib, a small molecule tyrosine kinase inhibitor approved across multiple cancer indications including renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and pancreatic neuroendocrine tumors, along with cobimetinib for melanoma and esaxerenone for hypertension. The company's lead late-stage program is zanzalintinib, a novel oral kinase inhibitor currently under FDA review for colorectal cancer with an extensive development program spanning multiple oncology indications including renal cell carcinoma, neuroendocrine tumors, and meningioma. Exelixis is advancing a diverse pipeline of phase 1 programs including XL309 (small molecule USP1 inhibitor), XB010 (antibody-drug conjugate targeting 5T

$44.46+13.56%1Y
EXEL · daily close · illustrative · 0 catalysts marked
$33$37$41$44$48Apr '25Aug '25Dec '25Apr '26
1Y high$46.851Y low$34.54range$12.31(36%)past catalysts

Pipeline14

Abiraterone
Phase 3Metastatic Prostate Cancer
Phase 3Prostate Cancer
small-molecule
Atezolizumab
Phase 3Hepatocellular Carcinoma
Phase 3Metastatic Prostate Cancer
Phase 3Colorectal Cancer
Phase 3Prostate Cancer
small-molecule
Cabozantinib
Phase 3Hepatocellular Carcinoma
Phase 3Renal Cell Carcinoma
Phase 3Metastatic Prostate Cancer
Phase 3Differentiated Thyroid Cancer
Phase 3Prostate Cancer
small-molecule
Enzalutamide
Phase 3Metastatic Prostate Cancer
Phase 3Prostate Cancer
small-molecule
Ipilimumab
Phase 3Renal Cell Carcinoma
small-molecule
Nivolumab
Phase 3Non-Clear Cell Renal Cell Carcinoma
Phase 3Renal Cell Carcinoma
small-molecule
Prednisone
Phase 3Metastatic Prostate Cancer
Phase 3Prostate Cancer
small-molecule
Regorafenib
Phase 3Colorectal Cancer
small-molecule
Sorafenib
Phase 3Hepatocellular Carcinoma
small-molecule
Sunitinib Malate
Phase 3Non-Clear Cell Renal Cell Carcinoma
small-molecule
XL092
Phase 3Non-Clear Cell Renal Cell Carcinoma
Phase 3Colorectal Cancer
small-molecule
Everolimus
Phase 2/3Pancreatic Neuroendocrine Tumor (pNET)
Phase 2/3Extra-Pancreatic Neuroendocrine Tumor (epNET)
small-molecule
Pembrolizumab
Phase 2/3Head and Neck Squamous Cell Carcinoma
small-molecule
Zanzalintinib
Phase 2/3Head and Neck Squamous Cell Carcinoma
Phase 2/3Pancreatic Neuroendocrine Tumor (pNET)
Phase 2/3Extra-Pancreatic Neuroendocrine Tumor (epNET)
small-molecule

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar